In a decentralised clinical trial, patients' assessments are (partly) transferred from the clinical trial site to the patients' home and might occur without any face to face interactions between patient and study personnel. In particular during the Covid-19 pandemic, decentralising clinical trials attracted considerable attention as one way to continue conducting trials during lockdowns and curfews. In this online event, experts in the field discuss the opportunities and challenges of decentralised clinical trials for the development of drugs and the promise they hold for modernising the way trials are conducted.
Who is this event intended for? Statisticians or those in other quantitative disciplines working on - or interested in - learning about decentralised clinical trials.
What is the benefit of attending? Attendees will hear about the application and opportunities of decentralised clinical trials in drug development from experts in the field, both statistical and operational.
Time: 13:30-16:30 BST (both days) | 14:30-17:30 CEST | 08:30-11:30 EDT
Speakers: David Wright (AstraZeneca), Magnus Jörnten-Karlsson (AstraZeneca), Magalie Hilton (Roche), Yashoda Sharma (DiMe), Khadija Rantell (MHRA), Rima Izem (Novartis) and Rachel Williams (GSK).